Cargando…

DNA Methylation Changes Following 5-azacitidine Treatment in Patients with Myelodysplastic Syndrome

DNA methyltransferase inhibitor, 5-azacitidine (AC) is effective in myelodysplastic syndromes (MDS) and can induce re-expression in cancer. We analyzed the methylation of 25 tumor suppressor genes in AC-treated MDS. Hypermethylation of CDKN2B, FHIT, ESR1, and IGSF4 gene was detected in 9/44 patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tran, Huong Thi Thanh, Kim, Hee Nam, Lee, Il-Kwon, Kim, Yeo-Kyeoung, Ahn, Jae-Sook, Yang, Deok-Hwan, Lee, Je-Jung, Kim, Hyeoung-Joon
Formato:	Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031004/ https://www.ncbi.nlm.nih.gov/pubmed/21286011 http://dx.doi.org/10.3346/jkms.2011.26.2.207

Ejemplares similares

Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations
por: Kim, Yoo-Jin, et al.
Publicado: (2013)

Improved Therapeutic Effect against Leukemia by a Combination of the Histone Methyltransferase Inhibitor Chaetocin and the Histone Deacetylase Inhibitor Trichostatin A
por: Tran, Huong Thi Thanh, et al.
Publicado: (2013)

Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2010)

Fludarabine-containing chemotherapy for patients with previously untreated low-grade non-Hodgkin's lymphoma
por: Ahn, Jae-Sook, et al.
Publicado: (2011)

Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patients
por: Hong, Seung-Dok, et al.
Publicado: (2011)

Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2015)

Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma
por: Yang, Deok-Hwan, et al.
Publicado: (2015)

The Impact of Hyperglycemia on Risk of Severe Infections during Early Period of Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2014)

Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
por: Ahn, Jae-Sook, et al.
Publicado: (2014)

OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2014)

Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
por: Park, Hyung-Chul, et al.
Publicado: (2012)

Successful Treatment of Pure Red Cell Aplasia with Rituximab in Patients after ABO-Compatible Allogeneic Hematopoietic Stem Cell Transplantation
por: Jung, Sung-Hoon, et al.
Publicado: (2012)

Oliguria as an early indicator of mortality risk in patients with multiple myeloma and renal impairment
por: Jung, Sung-Hoon, et al.
Publicado: (2015)

Polymorphisms in DNA Repair Genes and MDR1 and the Risk for Non-Hodgkin Lymphoma
por: Kim, Hee Nam, et al.
Publicado: (2014)

Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
por: Lee, Seung-Shin, et al.
Publicado: (2016)

A Case of Disseminated and Fulminant Plasmacytomas That Developed during Bortezomib Treatment
por: Bae, Soo-Young, et al.
Publicado: (2011)

Gene expression signatures associated with sensitivity to azacitidine in myelodysplastic syndromes
por: Kim, Kyuryung, et al.
Publicado: (2020)

STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2017)

Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma
por: Ahn, Jae-Sook, et al.
Publicado: (2013)

Fatal Interstitial Pneumonitis Rapidly Developed after the First Cycle of CHOP with Etoposide Combination Chemotherapy in a Patient with Lymphoma
por: Park, Hyung Chul, et al.
Publicado: (2013)

Treatment of BK virus-associated hemorrhagic cystitis with low-dose intravenous cidofovir in patients undergoing allogeneic hematopoietic cell transplantation
por: Lee, Seung-Shin, et al.
Publicado: (2015)

Multiple Intracranial Tuberculomas Mimicking Granulocytic Sarcomas in Acute Myeloid Leukemia
por: Ahn, Jae-Sook, et al.
Publicado: (2007)

Phase II Study of Paclitaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer
por: Hwang, Junyl, et al.
Publicado: (2008)

Azacitidine regulates DNA methylation of GADD45γ in myelodysplastic syndromes
por: Yang, Yanli, et al.
Publicado: (2020)

Safety and efficacy of azacitidine in myelodysplastic syndromes
por: Vigil, Carlos E, et al.
Publicado: (2010)

Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen
por: Jung, Sung-Hoon, et al.
Publicado: (2016)

Bi-weekly Chemotherapy of Paclitaxel and Cisplatin in Patients with Metastatic or Recurrent Esophageal Cancer
por: Cho, Sang-Hee, et al.
Publicado: (2005)

Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic
por: Hoang, My-Dung, et al.
Publicado: (2015)

Newly Developed Multiple Myeloma in a Patient with Primary T-Cell Lymphoma of Bone
por: Hwang, Jun-Eul, et al.
Publicado: (2008)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

Monosomal and complex karyotypes as prognostic parameters in patients with International Prognostic Scoring System higher risk myelodysplastic syndrome treated with azacitidine
por: Hwang, Kyung-Lim, et al.
Publicado: (2014)

Dry Dressing for Epidermal Sloughing after Subcutaneous Azacitidine Injection in a Myelodysplastic Syndrome
por: Lee, Jun Yong, et al.
Publicado: (2014)

The Clinical Outcome of FLAG Chemotherapy without Idarubicin in Patients with Relapsed or Refractory Acute Myeloid Leukemia
por: Lee, Se Ryeon, et al.
Publicado: (2009)

Dermatomyositis Associated with Cancer of Unknown Primary Site
por: Kim, Hyung Il, et al.
Publicado: (2007)

Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma
por: Jung, Sung-Hoon, et al.
Publicado: (2015)

Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome
por: Suh, Koung Jin, et al.
Publicado: (2016)

Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes
por: Cedena, M. Teresa, et al.
Publicado: (2017)

Hemolytic Anemia as a Sequela of Arsenic Intoxication Following Long-Term Ingestion of Traditional Chinese Medicine
por: Lee, Je-Jung, et al.
Publicado: (2004)

5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia
por: Ahn, Jae-Sook, et al.
Publicado: (2016)

Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL)
por: Kim, Therasa, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_olvo5vq0uu1clbpmtpi5nti66a